Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Feb. 24, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Trading Symbol	VTVT
Entity Registrant Name	vTv Therapeutics Inc.
Entity Central Index Key	0001641489
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 42,277,696
Class A Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		9,693,254
Class B Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		23,119,246

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 51,505,000	$ 88,003,000
Accounts receivable, net	0	69,000
Prepaid expenses and other current assets	612,000	1,114,000
Total current assets	52,117,000	89,186,000
Property and equipment, net	444,000	624,000
Other long-term assets	1,934,000	1,722,000
Total assets	54,495,000	91,532,000
Current liabilities:
Accounts payable and accrued expenses	11,413,000	6,627,000
Accounts payable and accrued expenses - related party		880,000
Deferred revenue	21,000	219,000
Total current liabilities	11,434,000	7,726,000
Notes payable	11,058,000
Other liabilities	433,000	245,000
Total liabilities	22,925,000	7,971,000
Commitments and contingencies
Redeemable noncontrolling interest	122,515,000	161,531,000
Stockholders’ deficit:
Additional paid-in capital	124,212,000	117,686,000
Accumulated deficit	(215,486,000)	(195,985,000)
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	(90,945,000)	(77,970,000)
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit	54,495,000	91,532,000
Class A Common Stock [Member]
Stockholders’ deficit:
Common stock value	97,000	92,000
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	97,000	92,000
Class B Common Stock [Member]
Stockholders’ deficit:
Common stock value	232,000	237,000
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	$ 232,000	$ 237,000

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015	Aug. 04, 2015	Jul. 29, 2015
Class A Common Stock [Member]
Common stock par value	$ 0.01	$ 0.01		$ 0.01
Common stock, shares authorized	100,000,000	100,000,000		100,000,000
Common stock, shares outstanding	9,693,254	9,156,686
Class B Common Stock [Member]
Common stock par value	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000		100,000,000
Common stock, shares outstanding	23,119,246	23,655,814

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 634,000	$ 519,000	$ 1,549,000
Operating expenses:
Research and development	44,953,000	27,237,000	17,378,000
Research and development – related party	795,000	2,347,000	1,351,000
General and administrative	9,906,000	9,077,000	11,717,000
Total operating expenses	55,654,000	38,661,000	30,446,000
Operating loss	(55,020,000)	(38,142,000)	(28,897,000)
Other loss	(22,000)	(838,000)	(503,000)
Other expense – related party		(392,000)	(623,000)
Interest income	87,000	40,000	4,000
Interest expense	(398,000)	(108,000)	(286,000)
Interest expense, net – related party		(1,667,000)	(5,727,000)
Investment loss – related party			(69,000)
Loss before income taxes and noncontrolling interest	(55,353,000)	(41,107,000)	(36,101,000)
Income tax provision	0	0	0
Net loss before noncontrolling interest	(55,353,000)	(41,107,000)	(36,101,000)
Less: net loss attributable to noncontrolling interest	(39,001,000)	(13,609,000)
Net loss attributable to vTv Therapeutics Inc.	$ (16,352,000)	$ (27,498,000)	$ (36,101,000)
Class A Common Stock [Member]
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (1.71)	$ (3.32)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	9,545,527	8,276,520

Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Noncontrolling Interest, Stockholders' and Members' Deficit - USD ($) $ in Thousands	Total	TransTech Pharma, LLC (TTP) [Member]	TransTech Pharma, LLC (TTP) [Member] Series F [Member]	High Point Pharmaceuticals, LLC (HPP) [Member] Series B [Member]	TransTech Pharma, LLC (TTP) and High Point Pharmaceuticals, LLC (HPP) [Member]	Redeemable Convertible Preferred Units [Member]	Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member] Series F [Member]	Redeemable Convertible Preferred Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member] Series B [Member]	Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) and High Point Pharmaceuticals, LLC (HPP) [Member]	Redeemable Noncontrolling Interest [Member]	Class A Common Stock [Member]	Class B Common Stock [Member]	Members Deficit [Member]	Members Deficit [Member] TransTech Pharma, LLC (TTP) [Member]	Members Deficit [Member] TransTech Pharma, LLC (TTP) [Member] Series F [Member]	Members Deficit [Member] High Point Pharmaceuticals, LLC (HPP) [Member] Series B [Member]	Members Deficit [Member] TransTech Pharma, LLC (TTP) and High Point Pharmaceuticals, LLC (HPP) [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2013	$ (303,733)													$ (303,733)
Beginning balance, redeemable convertible preferred units at Dec. 31, 2013						$ 229,370
Net loss	(36,101)													(36,101)
Issuance of preferred units - related party			$ 21,303	$ (3,726)				$ 52,697	$ 3,726							$ 21,303	$ (3,726)
Deemed contribution from a related party in a debt extinguishment	18,733													18,733
Repurchase of TTP Series F preferred, HPP Series B preferred, HPP and TTP common member units and warrants – related party					$ 14,016					$ (57,005)								$ 14,016
Change in redemption value of TTP redeemable convertible preferred units		$ (209,298)					$ 209,298								$ (209,298)
Ending balance at Dec. 31, 2014	(498,806)													(498,806)
Ending balance, redeemable convertible preferred units at Dec. 31, 2014						438,086
Net loss	(27,498)
Net loss prior to the Reorganization Transactions	(22,111)													(22,111)
Change in redemption value of TTP redeemable convertible preferred units		$ (75,077)					$ 75,077								$ (75,077)
Effect of Reorganization Transactions	596,244					$ (513,163)					$ (2,997)		$ 250	$ 595,994
Effect of Reorganization Transactions, shares													25,000,000
Issuance of Class A Common Stock in initial public offering, net of offering costs	104,445											$ 79							$ 104,366
Issuance of Class A Common Stock in initial public offering, net of offering costs, shares												7,812,500
Net loss subsequent to Reorganization Transactions	(5,387)										(13,609)									$ (5,387)
Share-based compensation	859																		859
Exchange of Class B Common Stock for Class A Common Stock	12,461										(12,461)	$ 13	$ (13)						12,461
Exchange of Class B Common Stock for Class A Common Stock, shares												1,344,186	(1,344,186)
Change in redemption value of noncontrolling interest	(190,598)										190,598									(190,598)
Ending balance at Dec. 31, 2015	(77,970)											$ 92	$ 237						117,686	(195,985)
Ending balance, shares at Dec. 31, 2015												9,156,686	23,655,814
Ending balance, redeemable noncontrolling interest at Dec. 31, 2015	161,531										161,531
Net loss	(16,352)										(39,001)									(16,352)
Share-based compensation	2,641																		2,641
Issuance of warrants to purchase Class A Common Stock	721																		721
Exchange of Class B Common Stock for Class A Common Stock	3,164										(3,164)	$ 5	$ (5)						3,164
Exchange of Class B Common Stock for Class A Common Stock, shares												536,568	(536,568)
Change in redemption value of noncontrolling interest	(3,149)										3,149									(3,149)
Ending balance at Dec. 31, 2016	(90,945)											$ 97	$ 232						$ 124,212	$ (215,486)
Ending balance, shares at Dec. 31, 2016												9,693,254	23,119,246
Ending balance, redeemable noncontrolling interest at Dec. 31, 2016	$ 122,515										$ 122,515

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss before noncontrolling interest	$ (55,353)	$ (41,107)	$ (36,101)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
(Gain) loss on disposal of PP&E, net	(2)	(7)	34
Depreciation expense	265	501	864
Share-based compensation expense	2,641	859
Change in fair value of contingent distribution		695
Amortization of debt discount	154
Amortization of debt discount – related party			4,773
Non-cash interest expense – distribution payable		27
Amortization of deferred financing costs			145
Impairment loss on carrying value of land		48	488
Bad debt (recovery) expense – related party		(3)	633
Impairment loss of marketable securities – related party			30
Change in fair value of marketable securities – related party			39
Changes in assets and liabilities:
Accounts receivable	69	(69)	(733)
Prepaid expenses and other assets	502	(1,020)	62
Employee loans receivable – related party	49	12	(43)
Receivable due from a related party			(623)
Note receivable		(20)	(231)
Other long-term assets	(261)	(1,598)	(4)
Accounts payable and accrued expenses	4,786	2,930	(2,324)
Accounts payable and accrued expenses – related party	(880)	2,458	2,144
Deferred revenue	(198)	219
Other liabilities	19	(871)	68
Net cash used in operating activities	(48,209)	(36,946)	(30,779)
Cash flows from investing activities:
Proceeds from sale of assets	4	25	334
Expenses paid related to disposal of HPCTC – related party			(140)
Purchases of property and equipment	(87)	(104)	(33)
Net cash (used in) provided by investing activities	(83)	(79)	161
Cash flows from financing activities:
Proceeds from issuance of vTv Therapeutics Inc. Class A Common Stock sold in initial public offering, net of offering costs		105,773
Proceeds from debt issuance	12,500
Repurchase of TTP preferred common member units and warrants – related party			(2,500)
Debt issuance costs	(673)
Payment of offering costs – related party		(1,329)
Proceeds from debt issuance – related party		19,289	33,561
Repayment of long-term obligations	(33)	(89)	(148)
Net cash provided by financing activities	11,794	123,644	30,913
Net (decrease) increase in cash and cash equivalents	(36,498)	86,619	295
Cash and equivalents, beginning of period	88,003	1,384	1,089
Cash and equivalents, end of period	51,505	88,003	1,384
Supplemental cash flow information:
Cash paid for interest	242	75	142
Non-cash activities:
Change in carrying value of net assets and liabilities not transferred to vTv Therapeutics, LLC as part of the Reorganization Transactions		2,747
Change in redemption value of noncontrolling interest	(3,149)	(190,598)
Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock	3,164	12,461
Issuance of warrants to purchase vTv Therapeutics Inc. Class A Common Stock	923
Repurchase of TTP and HPP preferred units, common membership units and warrants, in exchange for HPCTC and other liabilities, net of cash exchanged – related party			40,351
Deemed contribution from related party in a debt extinguishment – related party			18,733
Issuance of TTP Series F redeemable preferred units in exchange for debt – related party			$ 74,000
Redeemable Noncontrolling Interest [Member]
Non-cash activities:
Change in redemption value of noncontrolling interest	$ 3,149	$ 190,598

Description of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

Note 1: Description of Business and Basis of Presentation

Description of Business

vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”), was incorporated in the state of Delaware in April 2015. The Company was formed to discover and develop orally administered small molecule drug candidates to fill significant unmet medical needs.

Initial Public Offering

On August 4, 2015, vTv Therapeutics Inc. consummated its initial public offering (“IPO”) of 7,812,500 shares of its Class A common stock, par value $0.01 per share (“Class A Common Stock”), at a price of $15.00 per share. The IPO raised net proceeds of approximately $109.0 million after underwriting discounts and commissions but before expenses. vTv Therapeutics Inc. used the net proceeds of the IPO to acquire nonvoting common units (“vTv Units”) of vTv Therapeutics LLC (“vTv LLC”), an entity created to hold substantially all of the assets and operations of vTvx Holdings I LLC (formerly known as TransTech Pharma, LLC, “TTP” or “vTvx Holdings I”) and vTvx Holdings II LLC (formerly known as High Point Pharmaceuticals, LLC, “HPP” or “vTvx Holdings II” and together with vTvx Holdings I, the “Predecessors”), which assets and operations were transferred to such entity in a series of pre-IPO reorganization transactions (the “Reorganization Transactions”). vTv LLC is an entity under common control with vTv Therapeutics Inc. The Company intends to use the net proceeds from the IPO to fund clinical development, studies, and trials for its various products and other drug candidates, for working capital and other general corporate purposes.

Reorganization Transactions

During July 2015, TTP and HPP were renamed vTvx Holdings I LLC and vTvx Holdings II LLC, respectively. Concurrent with the IPO, the Company then entered into the following Reorganization Transactions, through which the operations of vTvx Holdings I and vTvx Holdings II were combined into vTv LLC:

(1)

vTvx Holdings I and vTvx Holdings II contributed substantially all of their assets, including all of their personnel and operations (the “Contributed Assets”), to a newly formed holding company, vTv Therapeutics Holdings LLC (“vTv Therapeutics Holdings”), in return for interests of vTv Therapeutics Holdings. Assets that were not contributed included restricted cash, certain receivables unrelated to the combined operations and land included in property and equipment, net. Liabilities that were not assumed included debt, a contingent distribution payable and other related party liabilities. All assets and liabilities that were not contributed or assumed remained with vTvx Holdings I and vTvx Holdings II and are not reflected in the Consolidated Balance Sheets as of December 31, 2016 and 2015;

(2)

vTv Therapeutics Holdings contributed the Contributed Assets to vTv LLC, a newly formed Delaware limited liability company, and, for administrative convenience, vTv Therapeutics Holdings directed that the assets be transferred directly to vTv LLC on behalf of vTv Therapeutics Holdings;

(3)

vTv Therapeutics Inc. amended and restated its certificate of incorporation and by-laws to provide for two classes of common stock:

(a)

Class A Common Stock, which represents economic interests and has one vote per share, and

(b)

Class B common stock, par value $0.01 per share (“Class B Common Stock”), which represents no economic interests and has one vote per share;

(4)

vTv LLC amended and restated its limited liability company agreement (the “Amended and Restated LLC Agreement”) to provide that it has two classes of membership units:

(a)

One managing member unit, which represents no economic interests and has 100% of the voting power of vTv LLC; and

(b)

Non-voting vTv Units, which represent economic interests;

(5)

vTv LLC issued the managing member unit to vTv Therapeutics Inc.;

(6)

vTv LLC issued 25,000,000 vTv Units to vTv Therapeutics Holdings; and

(7)

vTv Therapeutics Inc. issued 25,000,000 shares of Class B Common Stock, which represents no economic interests in the Company but has the right to cast one vote per share, to vTv Therapeutics Holdings which correspond to each vTv Unit held by vTv Therapeutics Holdings.

Below is a summary of the principal documents entered into in connection with the Reorganization Transactions:

Exchange Agreement - Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv LLC, the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for (i) shares of the Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the option of vTv Therapeutics Inc. (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the “Board of Directors”). On October 5, 2015, vTv Therapeutics Holdings was dissolved, and various holders of Class B Common Stock became parties to the Exchange Agreement.

Tax Receivable Agreement - The Tax Receivable Agreement among the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.

Investor Rights Agreement - The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration rights with respect to its shares of Class A Common Stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A Common Stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.

On October 1, 2015, vTvx Holdings I and vTvx Holdings II merged with and into vTv Therapeutics Holdings, with vTv Therapeutics Holdings continuing as the surviving limited liability company. On October 5, 2015, vTv Therapeutics Holdings was dissolved and made a liquidating distribution of shares of Class B Common Stock and the corresponding vTv Units to its members. As a result of the dissolution, M&F TTP Holdings LLC became the successor to vTv Therapeutics Holdings under the Investor Rights Agreement, the Exchange Agreement and the Tax Receivable Agreement pursuant to the terms of each respective agreement, and various other holders of Class B Common Stock became parties to the Exchange Agreement. On December 28, 2015, M&F TTP Holdings LLC contributed its shares of Class B Common Stock and the corresponding vTv Units to its subsidiary, M&F, which became the successor to M&F TTP Holdings LLC under the Investor Rights Agreement, Exchange Agreement and Tax Receivable Agreement pursuant to the terms of each respective agreement.

Reclassifications

To facilitate comparison of information across periods, certain reclassifications have been made to prior period amounts to conform to the current period’s presentation.

Principles of Consolidation

Subsequent to the IPO and the Reorganization Transactions, vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv LLC, the Company’s principal operating subsidiary, which is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.

The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its consolidated financial statements. Various holders own non-voting interests in vTv LLC, representing a 70.5% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 29.5% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional vTv Units or should the holders of vTv Units decide to exchange such units (together with shares of Class B Common Stock) for shares of Class A Common Stock (or cash) pursuant to the Exchange Agreement. vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the IPO in 2015 and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC outside of its obligations pertaining to the Loan Agreement as a co-borrower. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. The creditors of vTv LLC do not have any recourse to the general credit of vTv Therapeutics Inc except as allowed under the provisions of the Loan Agreement. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.

As the Reorganization Transactions were considered to be among entities under common control, the Consolidated Financial Statements for periods prior to the IPO and Reorganization Transactions have been adjusted to combine the historical financial statements of TTP and HPP (which were previously separate entities) for presentation purposes. The historical combined financial statements of these entities include assets and liabilities not transferred to the Company as part of the Reorganization Transactions as discussed above.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2: Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of the Company’s membership units, the fair value of redeemable preferred units, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.

There were no accounts receivable at December 31, 2016 and the balance of accounts receivable at December 31, 2015 was not significant.

Two customers represented 100% of the revenue earned during the years ended December 31, 2016 and 2015. Three customers represented 98% of the revenue during the year ended December 31, 2014.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Collaboration Revenue and Accounts Receivable

The majority of the Company’s collaboration revenue and accounts receivable is related to an exclusive global license agreement (the “License Agreement”) which the Company entered into on March 6, 2015 with Calithera Biosciences, Inc. (“Calithera”), granting Calithera exclusive world-wide rights to research, develop and commercialize the Company’s portfolio of hexokinase II inhibitors. Under the terms of the License Agreement, Calithera paid the Company an initial license fee of $0.6 million and may in the future pay potential development and regulatory milestone payments totaling up to $30.5 million for the first licensed product, an additional $77.0 million in potential sales-based milestones, as well as royalty payments, based on tiered sales of the first commercialized licensed product. In addition, Calithera agreed to fund up to $1.1 million during the first 12 months of the License Agreement for the costs associated with up to four full-time employees for the Company to develop additional hexokinase inhibitors under which the Company has recognized a total of $0.3 million from the inception of the contract through December 31, 2016. If Calithera develops additional licensed products, after achieving regulatory approval of the first licensed product, Calithera would owe additional regulatory milestone payments and additional royalty payments based on sales of such additional licensed products.

Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables.

Property and Equipment and other Long-lived Assets

The Company records property and equipment at cost less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to ten years. Leasehold improvements are depreciated over the shorter of the useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.

The estimated useful lives of property and equipment are as follows:

Asset Category	Useful Life (in years)
Laboratory equipment	7
Computers and hardware	3-5
Furniture and office equipment	3-7
Software	3
Leasehold improvements	Shorter of useful life or remaining term of lease

The Company periodically assesses it property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. During 2014, the Company determined that certain of its land assets met the criteria for held-for-sale accounting treatment after making the decision to sell the property. Accordingly, the Company adjusted the carrying value of such assets to the amount of the expected proceeds less costs of disposal, which was lower than the original carrying value. One of these properties was sold during the year ended December 31, 2015 and the other properties were not assumed by the Company as part of the Reorganization Transactions. There were no assets held for sale at December 31, 2016 or 2015.

Revenue Recognition

The Company uses the revenue recognition guidance established by ASC Topic 605, “Revenue Recognition.” The Company recognizes revenue when 1) persuasive evidence of an arrangement exists; 2) the service has been provided to the customer; 3) collection of the fee is reasonably assured; and 4) the amount of the fee to be paid by the customer is fixed or determinable. In determining the accounting for collaboration and alliance agreements, the Company follows the provisions of ASC Topic 605, Subtopic 25, “Multiple-Element Arrangements” (“ASC 605-25”) and ASC 808 (“Collaborative Arrangements”). ASC 605-25 provides guidance on whether an arrangement that involves multiple revenue-generating activities or deliverables should be divided into separate units of accounting for revenue recognition purposes and, if division is required, how the arrangement consideration should be allocated among the separate units of accounting. If a deliverable has value on a stand-alone basis, the Company treats the deliverable as a separate unit of accounting. If the arrangement constitutes separate units of accounting according to the separation criteria of ASC 605-25, the consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria is applied to each unit. The Company determines how to allocate amounts received under agreements among the separate units based on the respective selling price of each unit. If the arrangement constitutes a single unit of accounting, the revenue recognition policy must be determined for the entire arrangement and the consideration received is recognized over the period of inception through the date the last deliverable within the single unit of accounting is expected to be delivered.

Collaboration research and development revenue is earned and recognized as research is performed and related expenses are incurred. Non-refundable upfront fees are recorded as deferred revenue and recognized into revenue as license fees and milestones from collaborations on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, it recognizes non-refundable upfront fees into revenue ratably over the period during which the product deliverable is provided to the customer.

Revenue for non-refundable payments based on the achievement of milestone events under collaborative arrangements is recognized in accordance with ASC Topic 605, Subtopic 28, “Milestone Method” (“ASC 605-28”). Milestone events under the Company’s collaboration agreements may include research, development, regulatory, commercialization, and sales events. Under ASC 605-28, a milestone payment is recognized as revenue when the applicable event is achieved if the event meets the definition of a milestone and the milestone is determined to be substantive. ASC 605-28 defines a milestone event as an event having all of the following characteristics: (1) substantive uncertainty regarding achievement of the milestone event exists at the inception of the arrangement; (2) the event can only be achieved based, in whole or in part, on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (3) if achieved, the event will result in additional payment due to the Company. The Company also treats events that can only be achieved based, in whole or in part, on either a third party’s performance or a specific outcome resulting from a third party’s performance as milestone events if the criteria of ASC 605-28 are otherwise satisfied.

Research and development costs that are reimbursable under collaboration agreements are recorded in accordance with ASC Topic 605, Subtopic 45, “Principal-Agent Considerations.” Amounts reimbursed under a cost-sharing arrangement are reflected as reductions of research and development expense.

Fair Value of Financial Instruments

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

•

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

•

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

•

Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Research and Development

Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.

The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.

The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Consolidated Statements of Operations as the Company receives the related goods or services.

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations.

Income Taxes

In connection with the IPO, vTv Therapeutics Inc. was formed. From August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30, 2015, TTP and HPP were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level.

As a result of the Reorganization Transactions, vTv Therapeutics Inc. acquired vTv Units and is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC.

The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense.

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs.

The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.

The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s Consolidated Statement of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented.

Redeemable Convertible Preferred Units and Noncontrolling Interest

The Company initially recorded the redeemable convertible preferred units of the Predecessors at their fair values at issuance, net of issuance costs. All of the redeemable convertible preferred units were presented outside of permanent members’ deficit as the units were redeemable at holders’ option at the greater of (a) such series’ liquidation value (i.e., the original cost for each unit of such series (as adjusted for any unit split, unit dividend or other similar events)) plus all declared and unpaid distributions on such series and (b) such series’ fair market value (plus all declared but unpaid distributions on such series). The Company’s policy is to record changes in the redemption value of the redeemable convertible preferred units immediately as they occur and adjust the carrying value to equal the redemption value at each reporting period.

Similarly, the Company records the redeemable noncontrolling interest represented by the vTv Units and the Class B Common stock at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date.

See discussion and additional detail of the redeemable noncontrolling interest at Note 9.

Segment and Geographic Information

Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment.

Share-Based Compensation

Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and compensation expense is recognized for those awards earned over the service period. The grant date fair value of the awards is estimated using the Black-Scholes option pricing formula. Due to the lack of sufficient historical trading information with respect to its own shares, the Company estimates expected volatility based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. Due to a lack of historical exercise data, the Company estimates the expected life of its outstanding stock options using the simplified method specified under Staff Accounting Bulletin Topic 14.D.2. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee turnover rates.

Comprehensive Income

The Company does not have any components of other comprehensive income recorded within its Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Consolidated Financial Statements.

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue From Contracts With Customers”, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The ASU is based on the core principle that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. In addition, in March, April, and May 2016, the FASB issued final amendments to clarify the implementation guidance for principal versus agent considerations, identifying performance obligations and the accounting for licenses of intellectual property, and narrow-scope improvements and practical expedients, respectively. This ASU is effective for fiscal years beginning after December 15, 2017 including interim periods within that reporting period. To date, the Company has not generated any revenue from drug sales and its ability to recognize revenue from its collaboration and licensing agreements is contingent upon its ability to enter into such agreements in the future or the clinical success of investigational drug products subject to its current agreements, as such, the Company will continue to evaluate this guidance to determine the Company’s adoption method and the effect it will have on the Company’s Consolidated Financial Statements based on its potential future revenue sources.

In February 2015, the FASB issued ASU 2015-02, “Amendments to the Consolidation Analysis”, which significantly changes the consolidation analysis required under GAAP and will require companies to reevaluate all previous consolidation conclusions. The Company adopted the provisions of this guidance in the first quarter of 2016. The adoption of this statement did not have a significant impact on the Company’s Consolidated Financial Statements.

In April 2015, the FASB issued ASU No. 2015-05, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement”, (“ASU 2015-05”). The amendments in this update provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The Company adopted this guidance in the first quarter of 2016 on a prospective basis for all arrangements entered into or materially modified after the effective date. The adoption of this guidance did not have a significant impact on the Company’s Consolidated Financial Statements.

In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740) – Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The amendments in this update simplify the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This ASU is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company adopted this guidance in the first quarter of 2016 and did not retrospectively adjust prior period presentation. The adoption of this guidance did not have a significant impact on the Company’s Consolidated Financial Statements as the Company’s deferred tax assets were already classified as non-current.

In February 2016, the FASB issued ASU No. 2016-02, “Lease (Topic 842)” (“ASU 2016-02”), which increases transparency and comparability among companies accounting for lease transactions. The most significant change of this update will require the recognition by a lessee of lease assets and liabilities on its balance sheet for operating lease arrangements with lease terms greater than 12 months. This update will require a modified retrospective application which includes a number of optional practical expedients related to the identification and classification of leases commenced before the effective date. This ASU is effective for fiscal years and interim periods within those fiscal years, beginning after December 18, 2018. The adoption of this guidance will result in the recognition of additional assets and liabilities related to the Company’s operating leases within its Consolidated Balance Sheets.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is currently evaluating the guidance to determine the effect it will have on the Company’s Consolidated Financial Statements.

Share-Based Compensation

12 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation

Note 3: Share-Based Compensation

In conjunction with the IPO, the Board of Directors and sole stockholder adopted a long-term equity incentive plan, the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan (the “Plan”). The Plan provides for the grant of stock options, restricted stock, restricted stock units and other awards based on our Class A Common Stock to management, other key employees, consultants and non-employee directors on terms and subject to conditions as established by our Compensation Committee. In settlement of its obligations under this plan, the Company will issue new shares of Class A Common Stock. The maximum number of shares of our Class A Common Stock that has been approved and may be subject to awards under the Plan is 3.25 million, subject to adjustment in accordance with terms of the Plan.

During the years ended December 31, 2016 and 2015, the Company issued non-qualified stock option awards to certain employees, consultants and non-employee directors of the Company. These awards generally vest ratably over a three year period and expire after a term of ten years from the date of grant. For the years ended December 31, 2016 and 2015, the Company recognized $2.6 million and $0.9 of compensation expense related to share-based awards, respectively. Given that the Company has established a full valuation allowance against its deferred tax assets, the Company has recognized no tax benefit related to these awards. As of December 31, 2016, the Company had total unrecognized stock-based compensation expense of approximately $4.3 million, which is expected to be recognized on a straight-line basis over a weighted average period of 1.7 years. The weighted average grant date fair value for all option grants during the years ended December 31, 2016 and 2015 was $4.05 and $8.15 per option, respectively. As all of the outstanding awards were out-of-the-money at December 31, 2016, the aggregate intrinsic value of the in-the-money awards outstanding as of December 31, 2016 was $0.

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions during the years ended December 31, 2016 and 2015:

	2016		2015
Expected volatility	81.57% - 87.23%		83.84% - 88.23%
Expected life of option, in years	5.0 - 6.0		5.8 - 9.6
Risk-free interest rate	1.22% - 1.45%		1.72% - 2.25%
Expected dividend yield		0.00%		0.00%

The following table summarizes the activity related to the stock option awards for the year ended December 31, 2016 (in thousands, except per share amounts):

	Number of Shares			Weighted- Average Exercise Price
Awards outstanding at December 31, 2015		971,934		$	11.31
Granted		131,500			5.80
Forfeited		(7,333	)		7.65
Awards outstanding at December 31, 2016		1,096,101		$	10.68
Options exercisable at December 31, 2016		349,273		$	11.09
Weighted average remaining contractual term	8.7 Years
Options vested and expected to vest at December 31, 2016		1,059,523		$	10.74
Weighted average remaining contractual term	8.8 Years

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):

	2016		2015
Research and development	$	975	$	221
General and administrative		1,666		638
Total share-based compensation expense	$	2,641	$	859

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Property and Equipment

12 Months Ended

Dec. 31, 2016

Property Plant And Equipment [Abstract]

Property and Equipment

Note 4: Property and Equipment

Property and equipment consists of the following (in thousands):

	December 31,
	2016			2015
Laboratory equipment	$	6,962		$	7,085
Leasehold improvements		2,358			2,337
Computers and hardware		292			518
Software		855			1,307
Furniture and office equipment		431			465
Total property and equipment		10,898			11,712
Less: accumulated depreciation and amortization		(10,454	)		(11,088	)
Property and equipment, net	$	444		$	624

During the year ended December 31, 2014, the Company recognized an impairment loss on land of $0.5 million. The impairment loss is reflected in other (loss) income on the Consolidated Statements of Operations.

Depreciation expense, including amounts pertaining to assets held under capital leases, was $0.3 million, $0.5 million and $0.9 million for the years ended December 31, 2016, 2015 and 2014, respectively.

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2016

Payables And Accruals [Abstract]

Accounts Payable and Accrued Expenses

Note 5: Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following (in thousands):

	December 31,
	2016		2015
Accounts payable	$	3,060	$	3,262
Accrued development costs		6,305		1,912
Accrued payroll related costs		1,468		1,040
Accrued other		580		413
Total	$	11,413	$	6,627

Notes Payable

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Notes Payable

Note 6: Notes Payable

Notes payable consist of the following:

	2016			2015
Notes payable under the Loan Agreement	$	12,500		$	—
Less: Debt discount		(1,442	)		—
Total notes payable	$	11,058		$	—

On October 28, 2016, the Company and vTv LLC entered into the Loan Agreement under which the Company and vTv LLC may borrow up to $25.0 million in three tranches of $12.5 million, $7.5 million and $5.0 million, respectively.

The Company borrowed the first tranche of $12.5 million upon closing of the transaction on October 28, 2016. Subject to certain customary funding conditions, the second tranche of $7.5 million and the third tranche of $5.0 million are available for borrowing by the Company no later than March 31, 2017 and June 30, 2017, respectively. Availability of the third tranche is also subject to receipt of an executed term sheet setting forth certain agreed upon upfront and clinical and regulatory milestone payments for the licensing or purchase of one of the Company’s main drug candidates.

Each loan tranche bears interest at a floating rate equal to 10.5% plus the amount by which the one-month London Interbank Offer Rate (“LIBOR”) exceeds 0.5%.

The Company has agreed to repay the first tranche of $12.5 million on an interest only basis monthly until May 1, 2018 followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date for the first tranche loan on May 1, 2020. In addition, a final payment for the first tranche loan equal to $0.8 million will be due on May 1, 2020, or such earlier date specified in the Loan Agreement. The Company has agreed to repay any amounts advanced under the second and third tranches of $7.5 million and $5.0 million, respectively, in 18 monthly payments of interest only followed by 24 equal monthly payments of principal plus accrued interest through the scheduled maturity date for such loans which is 42 months following the date the Company draws down the second or third tranche loans, as applicable. In addition, a final payment equal to $0.5 million will be due on the scheduled maturity date for the second tranche loan and a final payment of $0.3 million will be due on the scheduled maturity date for the third tranche loan, or on such earlier date specified in the Loan Agreement.

If the Company repays all or a portion of the loan prior to the applicable maturity date, it will pay the Lenders a prepayment penalty fee, based on a percentage of the then outstanding principal balance equal to 4.0% during the first 18 months following the funding of the second tranche and 2.0% thereafter.

The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. Subject to certain conditions related to the Company’s Phase 3 clinical trial of azeliragon, the Company may be required to grant a security interest in its intellectual property. The Company has agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions.

The Loan Agreement includes customary affirmative and restrictive covenants, including, but not limited to, restrictions on the payment of dividends or other equity distributions and the incurrence of debt or liens upon the assets of the Company or its subsidiaries. The Loan Agreement does not contain any financial maintenance covenants. The Loan Agreement includes customary events of default, including payment defaults, covenant defaults, and material adverse change default. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% will be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

In connection with the Loan Agreement, the Company issued and is obligated to issue to the Lenders warrants to purchase shares of the Company’s Class A Common Stock (the “Warrants”). On October 28, 2016, the Company issued Warrants to purchase 152,580 shares of its Class A Common Stock at a per share exercise price of $6.39 per share, which aggregate exercise price represents 6.0% of the principal amount borrowed under the first tranche of the Loan Agreement and 3.0% of the amount available under the second tranche of the Loan Agreement. Additionally, to the extent the second tranche is borrowed under the Loan Agreement, the Company is obligated to issue to the Lenders Warrants with respect to a number of shares such that the aggregate exercise price of such warrants is equal to 3.0% of the principal amount of the second tranche upon funding of the second tranche. To the extent that the third tranche is borrowed under the Loan Agreement, the Company is obligated to issue to the Lenders Warrants with respect to a number of shares such that the aggregate exercise price of such warrants is equal to 6.0% of third loan tranche upon funding of the third tranche. In each instance, the Warrants have or will have an exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants. The Warrants will expire seven years from their date of issuance.

The Company incurred $0.7 million of costs in connection with the Loan Agreement. These costs, along with the allocated fair value of the Warrants issued of $0.9 million were treated as a debt discount, are offset against the carrying value of the notes payable in the Company’s Consolidated Balance Sheet as of December 31, 2016 and will be recognized as interest expense over the term of the first tranche using the effective interest method. The final payment for the first loan tranche of $0.8 million will be accrued as additional interest expense, using the effective interest method, over the term of the first tranche.

The Company recorded interest expense related to the Loan Agreement of $0.4 million for the year ended December 31, 2016. The annual effective interest rate on the note payable, including the amortization of the debt discounts and accretion of the final payments, is 17.7%.

Principal payments due under the terms of the Loan Agreement are as follows (in thousands):

2017	$	—
2018		3,646
2019		6,250
2020		2,604
2021		—
Total	$	12,500

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 7: Commitments and Contingencies

Legal Matters

From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.

Columbia University Agreement

In May 2015, the Company entered into a worldwide exclusive agreement with Columbia University (“Columbia”) to license certain intellectual property from Columbia. Under the agreement, the Company is obligated to pay to Columbia (1) an annual fee of $0.1 million from 2015 through 2021, (2) a potential regulatory milestone payment of $0.8 million and (3) potential royalty payments at a single digit royalty rate based on net sales of licensed products as defined in the agreement.

Lease Agreements

The Company leases various equipment and facilities under operating leases expiring at various dates through 2019. Rent expense for non-cancelable operating leases was $0.6 million, $0.6 million and $1.0 million for the years ended December 31, 2016, 2015 and 2014, respectively.

Future minimum lease payments under non-cancelable operating leases as of December 31, 2016 were as follows (in thousands):

Year Ending December 31,	Operating Leases
2017	$	471
2018		244
2019		6
2020		—
2021		—
Total	$	721

The Company has recognized an asset retirement obligation for an obligation in its facility lease that requires the Company to return the property to the same or similar condition at the end of the lease as existed when the Company began using the facility. Although the lease termination date is currently in 2018, the Company may be able to renegotiate the lease to extend its terms. Asset retirement obligations recorded as a component of other noncurrent liabilities in the Consolidated Balance Sheets were $0.2 million at both December 31, 2016 and 2015. An immaterial amount of accretion and depreciation expense was recognized in the years ended December 31, 2016 and 2015.

Stockholders' Equity

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Stockholders' Equity

Note 8: Stockholders’ Equity

On July 29, 2015, the Company amended and restated its certificate of incorporation to authorize 100,000,000 shares of Class A Common Stock, 100,000,000 shares of Class B Common Stock and 50,000,000 shares of preferred stock, par value $0.01 per share.

Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval. The holders of Class A Common Stock and Class B Common Stock will vote together as a single class on all matters submitted to stockholders for their vote or approval, except with respect to the amendment of certain provisions of the Company’s amended and restated certificate of incorporation that would alter or change the powers, preferences or special rights of the Class B Common Stock so as to affect them adversely, which amendments must be approved by a majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class, or as otherwise required by applicable law. The voting power of the outstanding Class B Common Stock (expressed as a percentage of the total voting power of all common stock) will be equal to the percentage of vTv Units not held by the Company. Holders of Class B Common Stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company.

On October 28, 2016, the Company entered into the Loan Agreement as discussed in Note 6. In connection with the Loan Agreement, the Company issued to the Lenders Warrants to purchase a total of 152,580 shares of the Company’s Class A Common Stock at an exercise price of $6.39 per share. Further, the Warrants issued related to the second tranche require the Company to issue an additional variable number of shares under the Warrants dependent upon the fair value of the Company’s Class A Common Stock as of the second tranche’s funding date. In each case, the Warrants have a term of seven years.

The Warrants issued with a determinable number of shares and exercise price were recorded as a component of additional paid-in capital within the Company’s Consolidated Balance Sheet as of December 31, 2016 based on their relative fair value. The Warrants issued for a variable number of shares were recorded as a component of other liabilities within the Consolidated Balance Sheet as of December 31, 2016. The related warrant liability will be adjusted to its fair value on a periodic basis until the associated warrants are cancelled or qualify for equity classification. For the year ended December 31, 2016, the Company recognized additional interest expense within the Consolidated Statement of Operations of a de minimus amount related to the adjustment of the warrant liability to its fair value.

Fair value of the Warrants was calculated as of October 28, 2016 using the methods described in Note 16 using the following assumptions:

Expected volatility		82.54%
Expected life of option, in years		7.0
Risk-free interest rate		1.63%
Expected dividend yield		0.00%

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Redeemable Noncontrolling Interest	12 Months Ended
Redeemable Noncontrolling Interest	Dec. 31, 2016
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest	Note 9: Redeemable Noncontrolling Interest The Company is subject to the Exchange Agreement with respect to the vTv Units representing the outstanding 70.5% noncontrolling interest in vTv LLC (see Note 1). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B Common Stock for (i) shares of Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20 day volume weighted average price of the Class A Common Stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December 31, 2016 and 2015, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $122.5 million and $161.5 million, respectively.

Related-Party Transactions	12 Months Ended
Related-Party Transactions	Dec. 31, 2016
Related Party Transactions [Abstract]
Related-Party Transactions	Note 10: Related-Party Transactions PharmaCore, Inc. Prior to its acquisition by Cambrex Corporation in October 2016, certain controlling shareholders of the Company also controlled PharmaCore, Inc. (“PharmaCore”) and PharmaCore was therefore considered to be a related party. The Company purchased chemistry and Good Manufacturing Practices manufacturing services from PharmaCore. Total purchases from PharmaCore, while it was considered to be a related party were $0.8 million, $2.3 million and $1.4 million for the years ended December 31, 2016, 2015 and 2014, respectively. On April 17, 2007, the Company’s Board of Directors approved $2.0 million of subordinated financing to be provided to PharmaCore. Advances were made and interest accrued before the Company entered into the Subordinated Promissory Note agreement (the “Note Agreement”) with PharmaCore on June 9, 2008. The Note Agreement was amended on April 23, 2010 to provide an additional $2.9 million of subordinated financing, with the same terms as the original note. The Note Agreement had a nine-year term, a fixed interest rate of 8.25% per annum, with maturity of June 1, 2017. No payments were required through December 31, 2014 with accrued interest capitalized into the principal balance. Thereafter, interest is to be paid quarterly. As part of the agreement, the Company received a warrant, exercisable for up to ten years, to purchase 370,370 common units of PharmaCore at an exercise price of $0.54 per unit. During the years ended December 31, 2015 and 2014, the Company recorded interest income of $0.4 million and $0.6 million, respectively, related to this financing. This receivable balance was not contributed to the Company as part of the Reorganization Transactions and, as such, no interest income was recognized during the year ended December 31, 2016. During the years ended December 31, 2015 and 2014, the Company recognized bad debt expense of $0.4 million and $0.6 million, respectively, for this Note Agreement due to the uncertainty of the receivable’s collectability. MacAndrews & Forbes Incorporated Subsequent to the Reorganization Transactions (Note 1) subsidiaries of MacAndrews & Forbes Incorporated (collectively “MacAndrews”) indirectly control 23,084,267 shares of Class B Common Stock. Further, as of December 31, 2016, MacAndrews holds 2,400,666 shares of the Company’s Class A Common Stock. As a result, MacAndrews’ holdings represent approximately 77.7% of the combined voting power of the Company’s outstanding common stock. The Company has entered into several agreements with MacAndrews or its affiliates as part of the Reorganization Transactions as further detailed below and in Note 1. Exchange Agreement Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for (i) shares of the Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire Board of Directors. As of December 31, 2016, MacAndrews has not exchanged any shares under the provisions of this agreement. Tax Receivable Agreement The Tax Receivable Agreement among the Company, M&F and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability nor has it made any payments pursuant to the Tax Receivable Agreement as of December 31, 2016. Investor Rights Agreement The Company is party to the Investor Rights Agreement with M&F, as a successor in interest to vTv Therapeutics Holdings. The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration rights with respect to its shares of Class A Common Stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A Common Stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.. Letter Agreement for Reimbursement of Fees and Expenses The Company entered into an agreement with MacAndrews & Forbes Group LLC (“M&F Group”) in which it agreed to reimburse M&F Group or its affiliates for certain out of pocket fees and expenses advanced by M&F Group in connection with the IPO. During the year ended December 31, 2015, the Company remitted payments to M&F Group or its affiliates of $1.3 million for such costs.

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	Note 11: Employee Benefit Plan The Company has a 401(k) retirement plan in which all of its full-time employees are eligible to participate. The plan provides for the Company to make discretionary 50% matching contributions up to a maximum of 6% of employees’ eligible compensation. The Company contributed $0.2 million, $0.1 million and $0.2 million to the plan for the years ended December 31, 2016, 2015 and 2014, respectively.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Note 12: Income Taxes

From August 1, 2015, vTv Therapeutics Inc. has been subject to U.S. federal income taxes as well as state taxes. Prior to July 30, 2015, TTP and HPP were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level. The Company did not record an income tax provision for the years ended December 31, 2016, 2015 and 2014.

As discussed in Note 1, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of December 31, 2016.

A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):

	December 31,
	2016			2015			2014
U.S. statutory tax benefit	$	(19,374	)	$	(14,387	)	$	(12,635	)
Partnership income (federal) not subject to tax to the Company		13,651			12,502			12,635
State taxes (net of federal benefit)		—			—			—
Losses with no benefit		5,723			1,885			—
Provision for income taxes	$	—		$	—		$	—
Effective income tax rate		0.0	%		0.0	%		0.0	%

Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):

	December 31,
	2016			2015
Deferred tax assets:
Net operating loss carryforwards	$	8,189		$	2,543
Share-based compensation		3			44
Investment in partnerships		1,844			1,476
Total deferred tax assets		10,036			4,063
Valuation allowance		(10,036	)		(4,063	)
Net deferred tax assets	$	—		$	—

The Company assesses the available positive evidence and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of existing deferred tax assets. A significant piece of objective negative evidence evaluated was the Company’s recent operating losses. Such objective evidence limits the ability to consider other subjective evidence, such as forecasts of profitability. On the basis of this evaluation, the Company concluded that its deferred tax assets were not realizable on a more-likely-than-not basis and recorded a full valuation allowance. As a result, the Company’s valuation allowance increased by $6.0 million.

The Company has federal net operating loss carryforwards of $22.1 million that will be available to offset future taxable income. Such carryforwards expire in 2035 and 2036 if not utilized.

The Company applies applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2016, the Company had no uncertain tax positions. There are no uncertain tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of December 31, 2016.

The Company files U.S. federal, Connecticut, New York, North Carolina and Virginia tax returns. The only open tax years for U.S. federal and the aforementioned states are December 31, 2016 and 2015.

Net Loss per Share

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Net Loss per Share

Note 13: Net Loss per Share

Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for the years ended December 31, 2016 and 2015 is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. Loss per share is not presented for the year ended December 31, 2014 as the Company did not have any economic interests prior to the date of the IPO and Reorganization Transactions through which it was given ownership in vTv LLC. Losses prior to the IPO and Reorganization Transactions would have been allocated to the original members of TTP and HPP. Loss per share for the year ended December 31, 2015 includes the losses recognized both prior and subsequent to the IPO and Reorganization Transactions.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A Common Stock is as follows (amounts in thousands, except per share amounts):

	Year Ended December 31,
	2016			2015			2014
Numerator:
Net loss	$	(55,353	)	$	(41,107	)	$	(36,101	)
Less: Net loss attributable to noncontrolling interests		(39,001	)		(13,609	)		—
Net loss attributable to vTv Therapeutics Inc., basic and diluted	$	(16,352	)	$	(27,498	)	$	(36,101	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		9,545,527			8,276,520
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(1.71	)	$	(3.32	)

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:

	Year Ended December 31,
	2016		2015		2014
Class B Common Stock ⁽¹⁾		23,119,246		23,655,814		—
Common stock options		1,096,101		971,934		—
Common stock warrants		152,580		—		—
Total		24,367,927		24,627,748		—

(1)

Shares of Class B Common Stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B Common Stock under the two-class method has not been provided. Each share of Class B Common Stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A Common Stock.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Data [Abstract]

Quarterly Financial Data (Unaudited)

Note 14: Quarterly Financial Data (Unaudited)

The following interim financial information presents our 2016 and 2015 results of operations on a quarterly basis (in thousands, except per share amounts):

	2016
	March 31			June 30			September 30			December 31
Revenues	$	376		$	182		$	38		$	38
Operating loss		(13,540	)		(14,639	)		(13,528	)		(13,313	)
Net loss before noncontrolling interest		(13,520	)		(14,617	)		(13,505	)		(13,711	)
Net loss attributable to vTv Therapeutics Inc.		(3,852	)		(4,457	)		(3,993	)		(4,050	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted ⁽¹⁾	$	(0.42	)	$	(0.47	)	$	(0.41	)	$	(0.42	)

	2015
	March 31			June 30			September 30			December 31
Revenues	$	50		$	110		$	133		$	226
Operating loss		(9,721	)		(7,889	)		(9,441	)		(11,090	)
Net loss before noncontrolling interest		(9,813	)		(10,412	)		(9,822	)		(11,059	)
Net loss attributable to vTv Therapeutics Inc.		(9,813	)		(10,412	)		(4,103	)		(3,169	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted ⁽¹⁾	$	(1.26	)	$	(1.33	)	$	(0.49	)	$	(0.35	)

(1)

Loss per share for the fiscal quarters ended in the 2015 fiscal year includes the losses recognized both prior and subsequent to the IPO and Reorganization Transactions. For the quarters ended March 31, 2015 and June 30, 2015, the weighed-average shares used to compute basic and diluted loss per share were based on the Class A Common Stock issued through the IPO (7,812,500 shares).

Predecessor Financial Arrangements	12 Months Ended
Predecessor Financial Arrangements	Dec. 31, 2016
Predecessor Financial Arrangements [Abstract]
Predecessor Financial Arrangements	Note 15: Predecessor Financial Arrangements The Reorganization Transactions discussed in Note 1 resulted in certain assets and liabilities of the Predecessors not being contributed to or assumed by the Company. As such, subsequent to the Reorganization Transactions, certain financial instruments and their related interest or fair value adjustments were no longer reflected within the Company’s Consolidated Financial Statements. Such financial instruments included the following: Note receivable from Former Officer - On March 30, 2007, TransTech Pharma, Inc. (“TTP Inc.”) entered into a promissory note (the “2007 Note”) with a former officer and director (“the Former Officer”), pursuant to which TTP Inc. loaned $4.8 million to the Former Officer. Promissory note on land - In June 2008, TTP Inc. entered into a promissory note with a financial institution secured by a deed of trust on land purchased in 2008. Distribution payable - On December 30, 2014, the boards of directors of TTP and HPP authorized a repurchase of units from the Former Officer and certain entities related to the officer (collectively with the Former Officer, the “Former Officer and Related Entities”) of TTP. The terms of the unit repurchase are stipulated in a Letter Agreement (the “Former Officer Agreement”) with the Former Officer and Related Entities. The Former Officer Agreement stipulated that these entities would repurchase all of the TTP and HPP issued and outstanding units owned by the Former Officer and Related Entities, including any warrants and options to purchase common units (collectively, the “Repurchased Units”). In exchange for the Repurchased Units, under the Former Officer Agreement, TTP and HPP agreed to make periodic cash payments to the Former Officer and Related Entities totaling $7.5 million between December 30, 2014 and September 30, 2017. Payments consisted of $2.5 million paid at closing of the agreement on December 30, 2014 and $5.0 million to be paid in eight equal quarterly installments beginning December 31, 2015. Uncommitted advance agreement - On March 28, 2014, TTP, HPP and M&F agreed to exchange all $116.2 million of outstanding principal and interest due to M&F under a Note and Equity Issuance Agreement (including amounts advanced under the initial agreement plus the promissory notes issued in 2013 and amounts advanced following the December 24, 2013 amendment) for 292,722,844 Series F redeemable convertible preferred units of TTP and 155,219,376 Series B redeemable convertible preferred units of HPP. Concurrently on March 28, 2014, TTP and HPP entered into an Uncommitted Advance Agreement with M&F and the Former Officer. As of December 30, 2014, the Former Officer was no longer party to this agreement. Contingent distribution - On December 31, 2014, TTP transferred 100% of its ownership interests in HPCTC to the Former Officer and agreed to make future distributions to the Former Officer (the “Contingent Distributions”). Perpetual securities - On March 28, 2014, TTP entered into a reaffirmation and pledge agreement (“Pledge Agreement”) with the Former Officer and Related Entities. Pursuant to the Pledge Agreement, the Former Officer granted a security interest to TTP in the Pledged Units to secure the Former Officer’s obligations to TTP under the 2007 Note and under the Pledge Agreement. On December 30, 2014, the Pledged Units were exchanged for TTP Perpetual Securities in the principal amount of approximately $6.0 million and HPP Perpetual Securities in the principal amount of approximately $0.5 million (the “Perpetual Securities”). The Perpetual Securities were initially recorded at their initial fair value of $6.6 million. The increase in the fair value of the perpetual securities during the year ended December 31, 2015, prior to the Reorganization Transactions was $0.1 million and is reflected in other income, net in the Consolidated Statements of Operations. Release agreement - On August 28, 2015, vTv Therapeutics Holdings, vTvx Holdings I, vTvx Holdings II, MacAndrews & Forbes Incorporated and M&F entered into a release agreement (the “Release Agreement”) with the Former Officer and Related Entities to settle certain obligations, including the obligation to pay the Contingent Distributions, under the Former Officer Agreement. Under the Release Agreement, vTv Therapeutics Holdings agreed to transfer 1,344,186 shares of Class B Common Stock and the same number of corresponding vTv Units to the Former Officer. Under the Release Agreement and the Former Officer Agreement, the 2007 Note owed by the Former Officer to TTP was also deemed discharged and canceled and the perpetual securities of vTvx Holdings I and vTvx Holdings II having principal amounts of $6.0 million and $0.5 million, respectively, held by the Former Officer, were repurchased by vTvx Holdings I and vTvx Holdings II in exchange therefor. On the same date, under the Exchange Agreement, the Former Officer exchanged those shares of Class B Common Stock and vTv Units for 1,344,186 shares of Class A Common Stock.

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Note 16: Fair Value of Financial Instruments

The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.

The fair value of the Company’s notes payable is considered to approximate its carrying value because it bears interest at a variable interest rate.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2016 (in thousands):

Balance at December 31, 2016

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability ⁽¹⁾

167

—

167

Total

167

—

167

(1)

Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.

	Changes in Level 3 Instruments for the years ended December 31, 2016, 2015 and 2014
	Balance at January 1		Net Change in fair value included in earnings		Net change in fair value ⁽¹⁾		Purchases / Issuance		Sales / Repurchases			Effect of Reorganization Transaction			Balance at December 31
2016
Warrant liability	$	—	$	—	$	—	$	167	$	—		$	—		$	167
Total	$	—	$	—	$	—	$	167	$	—		$	—		$	167

2015
TTP Redeemable preferred units	$	412,085	$	—	$	66,379	$	—	$	—		$	(478,464	)	$	—
HPP Redeemable preferred units		—		—		—		—		—			—			—
Consideration payable		4,897		—		—		—		—			(4,897	)		—
Note payable		6,594		115		—		—		—			(6,709	)		—
Contingent distribution		26,359		—		695		—		—			(27,054	)		—
Total	$	449,935	$	115	$	67,074	$	—	$	—		$	(517,124	)	$	—

2014
TTP Redeemable preferred units	$	14,676	$	—	$	399,106	$	52,697	$	(54,394	)	$	—		$	412,085
HPP Redeemable preferred units		—		—		—		—		—			—			—
Consideration payable		—		—		—		4,897		—			—			4,897
Note payable		—		—		—		6,594		—			—			6,594
Contingent distribution		—		—		—		26,359		—			—			26,359
Total	$	14,676	$	—	$	399,106	$	90,547	$	(54,394	)	$	—		$	449,935

(1)

The above represents the change in the fair value of the Company’s redeemable preferred units. See the Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Non-Controlling Interest, Stockholders’ and Members’ Deficit for additional changes in the carrying value of the Company’s redeemable preferred units.

There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the year ended December 31, 2016, 2015 or 2014.

The fair value of the warrant liability is determined using the Black-Scholes option pricing model. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the warrant liability as of December 31, 2016 were:

Annual volatility			83.28		%
Annual risk-free rate			2.30		%

Changes in the unobservable inputs noted above would impact the amount of the warranty liability. For the Company’s warrants, increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Use of Estimates

Concentration of Credit Risk

There were no accounts receivable at December 31, 2016 and the balance of accounts receivable at December 31, 2015 was not significant.

Two customers represented 100% of the revenue earned during the years ended December 31, 2016 and 2015. Three customers represented 98% of the revenue during the year ended December 31, 2014.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Collaboration Revenue and Accounts Receivable

Property and Equipment and other Long-lived Assets

The estimated useful lives of property and equipment are as follows:

Asset Category	Useful Life (in years)
Laboratory equipment	7
Computers and hardware	3-5
Furniture and office equipment	3-7
Software	3
Leasehold improvements	Shorter of useful life or remaining term of lease

Revenue Recognition

Fair Value of Financial Instruments

•

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

•

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

•

Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Research and Development

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations.

Income Taxes

Redeemable Convertible Preferred Units and Noncontrolling Interest

See discussion and additional detail of the redeemable noncontrolling interest at Note 9.

Segment and Geographic Information

Share-Based Compensation

Comprehensive Income

Recently Issued Accounting Pronouncements

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Assumptions Used to Estimate Fair Value of Stock Option Awards Granted

	2016		2015
Expected volatility	81.57% - 87.23%		83.84% - 88.23%
Expected life of option, in years	5.0 - 6.0		5.8 - 9.6
Risk-free interest rate	1.22% - 1.45%		1.72% - 2.25%
Expected dividend yield		0.00%		0.00%

Summary of Stock Award Activity for the Period

The following table summarizes the activity related to the stock option awards for the year ended December 31, 2016 (in thousands, except per share amounts):

	Number of Shares			Weighted- Average Exercise Price
Awards outstanding at December 31, 2015		971,934		$	11.31
Granted		131,500			5.80
Forfeited		(7,333	)		7.65
Awards outstanding at December 31, 2016		1,096,101		$	10.68
Options exercisable at December 31, 2016		349,273		$	11.09
Weighted average remaining contractual term	8.7 Years
Options vested and expected to vest at December 31, 2016		1,059,523		$	10.74
Weighted average remaining contractual term	8.8 Years

Summary of Compensation Expense Related to Grants of Stock Options

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):

	2016		2015
Research and development	$	975	$	221
General and administrative		1,666		638
Total share-based compensation expense	$	2,641	$	859

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2016

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consists of the following (in thousands):

	December 31,
	2016			2015
Laboratory equipment	$	6,962		$	7,085
Leasehold improvements		2,358			2,337
Computers and hardware		292			518
Software		855			1,307
Furniture and office equipment		431			465
Total property and equipment		10,898			11,712
Less: accumulated depreciation and amortization		(10,454	)		(11,088	)
Property and equipment, net	$	444		$	624

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2016

Payables And Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued expenses consist of the following (in thousands):

	December 31,
	2016		2015
Accounts payable	$	3,060	$	3,262
Accrued development costs		6,305		1,912
Accrued payroll related costs		1,468		1,040
Accrued other		580		413
Total	$	11,413	$	6,627

Notes Payable (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Schedule of Notes Payable

Notes payable consist of the following:

	2016			2015
Notes payable under the Loan Agreement	$	12,500		$	—
Less: Debt discount		(1,442	)		—
Total notes payable	$	11,058		$	—

Schedule of Principal Payments Due Under Terms of Loan Agreement

Principal payments due under the terms of the Loan Agreement are as follows (in thousands):

2017	$	—
2018		3,646
2019		6,250
2020		2,604
2021		—
Total	$	12,500

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases

Future minimum lease payments under non-cancelable operating leases as of December 31, 2016 were as follows (in thousands):

Year Ending December 31,	Operating Leases
2017	$	471
2018		244
2019		6
2020		—
2021		—
Total	$	721

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2016

Warrant Liability [Member]

Assumptions Used to Calculate Fair Value of Warrants

Fair value of the Warrants was calculated as of October 28, 2016 using the methods described in Note 16 using the following assumptions:

Expected volatility		82.54%
Expected life of option, in years		7.0
Risk-free interest rate		1.63%
Expected dividend yield		0.00%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):

	December 31,
	2016			2015			2014
U.S. statutory tax benefit	$	(19,374	)	$	(14,387	)	$	(12,635	)
Partnership income (federal) not subject to tax to the Company		13,651			12,502			12,635
State taxes (net of federal benefit)		—			—			—
Losses with no benefit		5,723			1,885			—
Provision for income taxes	$	—		$	—		$	—
Effective income tax rate		0.0	%		0.0	%		0.0	%

Schedule of Net Deferred Tax Assets/(Liabilities)

Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):

	December 31,
	2016			2015
Deferred tax assets:
Net operating loss carryforwards	$	8,189		$	2,543
Share-based compensation		3			44
Investment in partnerships		1,844			1,476
Total deferred tax assets		10,036			4,063
Valuation allowance		(10,036	)		(4,063	)
Net deferred tax assets	$	—		$	—

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock

	Year Ended December 31,
	2016			2015			2014
Numerator:
Net loss	$	(55,353	)	$	(41,107	)	$	(36,101	)
Less: Net loss attributable to noncontrolling interests		(39,001	)		(13,609	)		—
Net loss attributable to vTv Therapeutics Inc., basic and diluted	$	(16,352	)	$	(27,498	)	$	(36,101	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		9,545,527			8,276,520
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(1.71	)	$	(3.32	)

Schedule of Potentially Dilutive Securities Not Included in Calculation of Dilutive Net Loss per Share

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:

	Year Ended December 31,
	2016		2015		2014
Class B Common Stock ⁽¹⁾		23,119,246		23,655,814		—
Common stock options		1,096,101		971,934		—
Common stock warrants		152,580		—		—
Total		24,367,927		24,627,748		—

(1)

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Data [Abstract]

Schedule of Quarterly Financial Information

The following interim financial information presents our 2016 and 2015 results of operations on a quarterly basis (in thousands, except per share amounts):

	2016
	March 31			June 30			September 30			December 31
Revenues	$	376		$	182		$	38		$	38
Operating loss		(13,540	)		(14,639	)		(13,528	)		(13,313	)
Net loss before noncontrolling interest		(13,520	)		(14,617	)		(13,505	)		(13,711	)
Net loss attributable to vTv Therapeutics Inc.		(3,852	)		(4,457	)		(3,993	)		(4,050	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted ⁽¹⁾	$	(0.42	)	$	(0.47	)	$	(0.41	)	$	(0.42	)

	2015
	March 31			June 30			September 30			December 31
Revenues	$	50		$	110		$	133		$	226
Operating loss		(9,721	)		(7,889	)		(9,441	)		(11,090	)
Net loss before noncontrolling interest		(9,813	)		(10,412	)		(9,822	)		(11,059	)
Net loss attributable to vTv Therapeutics Inc.		(9,813	)		(10,412	)		(4,103	)		(3,169	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted ⁽¹⁾	$	(1.26	)	$	(1.33	)	$	(0.49	)	$	(0.35	)

(1)

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Summarizes the Conclusions Reached Regarding Fair Value Measurements

The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2016 (in thousands):

Balance at December 31, 2016

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability ⁽¹⁾

167

—

167

Total

167

—

167

(1)

	Changes in Level 3 Instruments for the years ended December 31, 2016, 2015 and 2014
	Balance at January 1		Net Change in fair value included in earnings		Net change in fair value ⁽¹⁾		Purchases / Issuance		Sales / Repurchases			Effect of Reorganization Transaction			Balance at December 31
2016
Warrant liability	$	—	$	—	$	—	$	167	$	—		$	—		$	167
Total	$	—	$	—	$	—	$	167	$	—		$	—		$	167

2015
TTP Redeemable preferred units	$	412,085	$	—	$	66,379	$	—	$	—		$	(478,464	)	$	—
HPP Redeemable preferred units		—		—		—		—		—			—			—
Consideration payable		4,897		—		—		—		—			(4,897	)		—
Note payable		6,594		115		—		—		—			(6,709	)		—
Contingent distribution		26,359		—		695		—		—			(27,054	)		—
Total	$	449,935	$	115	$	67,074	$	—	$	—		$	(517,124	)	$	—

2014
TTP Redeemable preferred units	$	14,676	$	—	$	399,106	$	52,697	$	(54,394	)	$	—		$	412,085
HPP Redeemable preferred units		—		—		—		—		—			—			—
Consideration payable		—		—		—		4,897		—			—			4,897
Note payable		—		—		—		6,594		—			—			6,594
Contingent distribution		—		—		—		26,359		—			—			26,359
Total	$	14,676	$	—	$	399,106	$	90,547	$	(54,394	)	$	—		$	449,935

(1)

Summary of Significant Inputs Utilized in the Valuation of Warrant Liability

Significant inputs utilized in the valuation of the warrant liability as of December 31, 2016 were:

Annual volatility			83.28		%
Annual risk-free rate			2.30		%

Description of Business and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands		12 Months Ended
	Aug. 04, 2015 USD ($) Vote $ / shares shares	Dec. 31, 2016 Vote $ / shares	Dec. 31, 2015 USD ($) $ / shares shares	Jul. 29, 2015 $ / shares
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from initial public offering \| $			$ 105,773
vTv Therapeutics LLC [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC		70.50%
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC		29.50%
vTv Therapeutics Holdings and M&F TTP Holdings LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Description of tax receivable agreement		The Tax Receivable Agreement among the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
Amount of cash savings percentage	85.00%
vTv Therapeutics LLC Units [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Amended and restated limited liability company agreement		two classes of membership units: (a) One managing member unit, which represents no economic interests and has 100% of the voting power of vTv LLC; and (b) Non-voting vTv Units, which represent economic interests;
Voting power percentage of one managing member unit		100.00%
Common member unit, share issued \| shares	25,000,000
Class A Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued through IPO \| shares			7,812,500
Common stock par value \| $ / shares		$ 0.01	$ 0.01	$ 0.01
Common stock, vote per share \| Vote	1	1
Class A Common Stock [Member] \| vTv Therapeutics LLC [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC		70.50%
Class A Common Stock [Member] \| IPO [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued through IPO \| shares	7,812,500
Common stock par value \| $ / shares	$ 0.01
Common stock issued price per share \| $ / shares	$ 15.00
Net proceeds from initial public offering \| $	$ 109,000
Class B Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued through IPO \| shares	25,000,000
Common stock par value \| $ / shares	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common stock, vote per share \| Vote	1	1

Summary of Significant Accounting Policies - Additional Information (Detail)		12 Months Ended			22 Months Ended
	Mar. 06, 2015 USD ($)	Dec. 31, 2016 USD ($) Customer Segment	Dec. 31, 2015 USD ($) Customer Property	Dec. 31, 2014 Customer	Dec. 31, 2016 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Accounts receivable		$ 0	$ 69,000		$ 0
Number of properties sold \| Property			1
Assets held for sale		0	$ 0		0
Significant interest or penalties incurred related to income taxes		$ 0
Number of reportable segments \| Segment		1
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives		P10Y
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives		P3Y
Collaborative Arrangement [Member]
Summary Of Significant Accounting Policies [Line Items]
License fee received	$ 600,000
Potential sales-based milestones based on tiered sales of the first commercialized licensed product	77,000,000
Collaboration revenue recognized					$ 300,000
Collaborative Arrangement [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Potential development and regulatory milestone payments for the first licensed product	30,500,000
Additional payments for employee services	$ 1,100,000
Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer		2	2	3
Revenue [Member] \| Customer [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		100.00%	100.00%	98.00%

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2016
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	P3Y
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	P10Y
Laboratory Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	7 years
Computers and Hardware [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Computers and Hardware [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	5 years
Furniture and Office Equipment [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Furniture and Office Equipment [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	7 years
Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Leasehold Improvements [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	Shorter of useful life or remaining term of lease

Share-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-qualified stock option awards vesting period	3 years	3 years
Non-qualified stock option awards expiration term	10 years	10 years
Compensation expense related to share-based awards	$ 2,641,000	$ 859,000
Tax benefit related to stock option awards	0	$ 0
Unrecognized compensation cost related to non-vested share-based compensation arrangements	$ 4,300,000
Weighted average period to recognize unrecognized share-based compensation cost	1 year 8 months 12 days
Weighted average grant date fair value of options granted	$ 4.05	$ 8.15
Aggregate intrinsic value of outstanding awards	$ 0
2015 Omnibus Equity Incentive Plan [Member] \| Class A Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares to be awarded	3,250,000

Share-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Option Awards Granted (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility	81.57%	83.84%
Expected life of option, in years	5 years	5 years 9 months 18 days
Risk-free interest rate	1.22%	1.72%
Maximum [Member]
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility	87.23%	88.23%
Expected life of option, in years	6 years	9 years 7 months 6 days
Risk-free interest rate	1.45%	2.25%

Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share Based Arrangements To Obtain Goods And Services [Abstract]
Number of shares awards outstanding, Beginning balance \| shares	971,934
Number of shares, Granted \| shares	131,500
Number of shares, Forfeited \| shares	(7,333)
Number of shares awards outstanding, Ending balance \| shares	1,096,101
Number of shares, Options exercisable \| shares	349,273
Number of shares options exercisable, Weighted average remaining contractual term	8 years 8 months 12 days
Number of shares, Options vested and expected to vest \| shares	1,059,523
Number of shares options vested and expected to vest, Weighted average remaining contractual term	8 years 9 months 18 days
Weighted-average exercise price awards outstanding, Beginning balance \| $ / shares	$ 11.31
Weighted-average exercise price, Granted \| $ / shares	5.80
Weighted-average exercise price, Forfeited \| $ / shares	7.65
Weighted-average exercise price awards outstanding, Ending balance \| $ / shares	10.68
Weighted-average exercise price, Options exercisable \| $ / shares	11.09
Weighted-average exercise price, Options vested and expected to vest \| $ / shares	$ 10.74

Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 2,641	$ 859
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	975	221
General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 1,666	$ 638

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Total property and equipment	$ 10,898	$ 11,712
Less: accumulated depreciation and amortization	(10,454)	(11,088)
Property and equipment, net	444	624
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	6,962	7,085
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	2,358	2,337
Computers and Hardware [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	292	518
Software [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	855	1,307
Furniture and Office Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	$ 431	$ 465

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Impairment loss on land		$ 48	$ 488
Depreciation expense	$ 265	$ 501	$ 864

Accounts Payable and Accrued Expenses - Accounts payable and accrued expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Accounts payable	$ 3,060	$ 3,262
Accrued development costs	6,305	1,912
Accrued payroll related costs	1,468	1,040
Accrued other	580	413
Total	$ 11,413	$ 6,627

Notes Payable - Schedule of Notes Payable (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Debt Disclosure [Abstract]
Notes payable under the Loan Agreement	$ 12,500
Less: Debt discount	(1,442)
Total notes payable	$ 11,058

Notes Payable - Additional Information (Detail)		12 Months Ended
Notes Payable - Additional Information (Detail)	Oct. 28, 2016 USD ($) Tranche Installment $ / shares shares	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Costs incurred in connection with loan agreement		$ 673,000
Allocated fair value of warrants issued		$ 923,000
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Effective interest rate on note payable		17.70%
Loan and Security Agreement [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate floor	0.50%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Loan borrowing capacity	$ 25,000,000
Number of tranches \| Tranche	3
Debt instrument, interest rate floor	10.50%
Variable rate basis		one-month LIBOR
Interest rate description		Each loan tranche bears interest at a floating rate equal to 10.5% plus the amount by which the one-month London Interbank Offer Rate (“LIBOR”) exceeds 0.5%.
Additional default interest rate	5.00%
Warrants to purchase shares of common stock \| shares	152,580
Exercise price of warrants \| $ / shares	$ 6.39
Warrant exercise price condition		Exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants.
Warrants expiration period	7 years
Costs incurred in connection with loan agreement	$ 700,000
Allocated fair value of warrants issued		$ 900,000
Interest expense related to loan agreement		$ 400,000
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Prepayments for First 18 Months [Member]
Debt Instrument [Line Items]
Prepayment penalty fee	4.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Prepayments Thereafter [Member]
Debt Instrument [Line Items]
Prepayment penalty fee	2.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche One [Member]
Debt Instrument [Line Items]
Loan borrowing capacity	$ 12,500,000
Tranches expiration date	Oct. 28, 2016
Debt instrument, payment terms		The Company has agreed to repay the first tranche of $12.5 million on an interest only basis monthly until May 1, 2018 followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date for the first tranche loan on May 1, 2020.
Debt instrument, final payment	$ 800,000
Debt instrument, maturity date	May 01, 2020
Warrant shares percentage issued of loan amount	6.00%
Final payment, accrued additional interest expense		$ 800,000
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Two [Member]
Debt Instrument [Line Items]
Loan borrowing capacity	$ 7,500,000
Tranches expiration date	Mar. 31, 2017
Debt instrument, final payment	$ 500,000
Warrant shares percentage issued of loan amount	3.00%
Additional warrant shares percentage issued of loan amount	3.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Three [Member]
Debt Instrument [Line Items]
Loan borrowing capacity	$ 5,000,000
Tranches expiration date	Jun. 30, 2017
Debt instrument, final payment	$ 300,000
Additional warrant shares percentage issued of loan amount	6.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Two and Three [Member]
Debt Instrument [Line Items]
Debt instrument, payment terms		The Company has agreed to repay any amounts advanced under the second and third tranches of $7.5 million and $5.0 million, respectively, in 18 monthly payments of interest only followed by 24 equal monthly payments of principal plus accrued interest through the scheduled maturity date for such loans which is 42 months following the date the Company draws down the second or third tranche loans, as applicable.
Number of installments for loan repayment \| Installment	42
Number of installments for interest payment \| Installment	18
Number of installments for principal and interest payment \| Installment	24

Notes Payable - Schedule of Principal Payments Due Under Terms of Loan Agreement (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Debt Disclosure [Abstract]
2018	$ 3,646
2019	6,250
2020	2,604
Total	$ 12,500

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	May 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Lease termination description		operating leases expiring at various dates through 2019
Asset retirement obligations, noncurrent		$ 0.2	$ 0.2
Non-cancelable Operating Leases [Member]
Commitments And Contingencies [Line Items]
Rent expense for operating leases		$ 0.6	$ 0.6	$ 1.0
Facility Lease
Commitments And Contingencies [Line Items]
Lease termination year		2018
Columbia University [Member]
Commitments And Contingencies [Line Items]
Annual fee obligated to pay under the agreement	$ 0.1
Annual fee payment obligation period		2015 through 2021
Columbia University [Member] \| Regulatory Milestone Payment [Member]
Commitments And Contingencies [Line Items]
Potential milestone payment	$ 0.8

Commitments and Contingencies - Summary of Future Minimum Lease Payments Under Non-cancelable Operating leases (Detail) - Non-cancelable Operating Leases [Member] $ in Thousands	Dec. 31, 2016 USD ($)
Commitments And Contingencies [Line Items]
2017	$ 471
2018	244
2019	6
Total	$ 721

Stockholders' Equity - Additional Information (Detail)			12 Months Ended
Stockholders' Equity - Additional Information (Detail)	Oct. 28, 2016 $ / shares shares	Aug. 04, 2015 Vote $ / shares	Dec. 31, 2016 Vote $ / shares shares	Dec. 31, 2015 $ / shares shares	Jul. 29, 2015 $ / shares shares
Class Of Stock [Line Items]
Preferred stock, shares authorized \| shares					50,000,000
Preferred stock par value \| $ / shares					$ 0.01
Common stock, voting rights			Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval.
Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Loan and Security Agreement [Member]
Class Of Stock [Line Items]
Warrants to purchase shares of common stock \| shares	152,580
Exercise price of warrants \| $ / shares	$ 6.39
Warrants expiration period	7 years
Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized \| shares			100,000,000	100,000,000	100,000,000
Common stock par value \| $ / shares			$ 0.01	$ 0.01	$ 0.01
Common stock, vote per share \| Vote		1	1
Class B Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized \| shares			100,000,000	100,000,000	100,000,000
Common stock par value \| $ / shares		$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common stock, vote per share \| Vote		1	1

Stockholders' Equity - Assumptions Used to Calculate Fair Value of Warrants (Detail) - Warrant Liability [Member]		12 Months Ended
	Oct. 28, 2016	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected volatility	82.54%	83.28%
Expected life of option, in years	7 years
Risk-free interest rate	1.63%	2.30%
Expected dividend yield	0.00%

Redeemable Noncontrolling Interest - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Noncontrolling Interest [Line Items]
Redemption amount of noncontrolling interest	$ 122.5	$ 161.5
Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Number of days used to determine exchange value based on weighted average price of Class A common stock	20 days
Class A Common Stock [Member] \| Exchange of Redeemable Non controlling Interest To Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Stock conversion ratio	1.00
vTv Therapeutics LLC [Member]
Noncontrolling Interest [Line Items]
Noncontrolling interest ownership percentage	70.50%
vTv Therapeutics LLC [Member] \| Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Noncontrolling interest ownership percentage	70.50%

Related-Party Transactions - Additional Information (Detail) - USD ($)			12 Months Ended
	Apr. 23, 2010	Apr. 17, 2007	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Bad debt expense – related party				$ (3,000)	$ 633,000
Reimbursement of offering costs - related party				1,329,000
PharmaCore, Inc. [Member]
Related Party Transaction [Line Items]
Total purchases from related party			$ 800,000	2,300,000	1,400,000
Financing to related party	$ 2,900,000	$ 2,000,000
Note agreement, term			9 years
Note agreement, interest rate	8.25%
Note agreement, maturity date			Jun. 01, 2017
Capitalization of accrued interest					0
Warrant exercisable term			10 years
Shares available under warrant exercised	370,370
Warrants, Exercise price per unit			$ 0.54
Interest income recorded			$ 0	400,000	600,000
Bad debt expense – related party				400,000	$ 600,000
MacAndrews & Forbes Incorporated [Member]
Related Party Transaction [Line Items]
Ownership percentage of majority owner			77.70%
Amount of cash savings percentage			85.00%
Description of tax receivable agreement			The Tax Receivable Agreement among the Company, M&F and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
MacAndrews & Forbes Incorporated [Member] \| Class B Common Stock [Member]
Related Party Transaction [Line Items]
Shares held by related party			23,084,267
MacAndrews & Forbes Incorporated [Member] \| Class A Common Stock [Member]
Related Party Transaction [Line Items]
Shares held by related party			2,400,666
M&F Group [Member]
Related Party Transaction [Line Items]
Reimbursement of offering costs - related party				$ 1,300,000

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Compensation And Employee Benefit Plans [Abstract]
Percentage of employer contribution	50.00%
Maximum annual contribution per employee	6.00%
Contributions made by employer	$ 0.2	$ 0.1	$ 0.2

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Income tax provision	$ 0	$ 0	$ 0
Increase in valuation allowance	6,000,000
Uncertain tax positions	0
Increase decrease in uncertain tax position reasonably possible	0
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 22,100,000
Federal [Member] \| Minimum [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date	2035
Federal [Member] \| Maximum [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date	2036
M&F TTP Holdings LLC [Member]
Income Taxes [Line Items]
Amount of cash savings percentage	85.00%

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
U.S. statutory tax benefit	$ (19,374)	$ (14,387)	$ (12,635)
Partnership income (federal) not subject to tax to the Company	13,651	12,502	$ 12,635
Losses with no benefit	$ 5,723	$ 1,885
Effective income tax rate	0.00%	0.00%	0.00%

Income Taxes - Schedule of Net Deferred Tax Assets/(Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 8,189	$ 2,543
Share-based compensation	3	44
Investment in partnerships	1,844	1,476
Total deferred tax assets	10,036	4,063
Valuation allowance	$ (10,036)	$ (4,063)

Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Numerator:
Net loss	$ (13,711)	$ (13,505)	$ (14,617)	$ (13,520)	$ (11,059)	$ (9,822)	$ (10,412)	$ (9,813)	$ (55,353)	$ (41,107)	$ (36,101)
Less: Net loss attributable to noncontrolling interests									(39,001)	(13,609)
Net loss attributable to vTv Therapeutics Inc.	$ (4,050)	$ (3,993)	$ (4,457)	$ (3,852)	$ (3,169)	$ (4,103)	$ (10,412)	$ (9,813)	$ (16,352)	$ (27,498)	$ (36,101)
Class A Common Stock [Member]
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted									9,545,527	8,276,520
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.42)	$ (0.41)	$ (0.47)	$ (0.42)	$ (0.35)	$ (0.49)	$ (1.33)	$ (1.26)	$ (1.71)	$ (3.32)

Net Loss per Share - Schedule of Potentially Dilutive Securities Not Included in Calculation of Dilutive Net Loss per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	24,367,927	24,627,748
Class B Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	23,119,246	23,655,814
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	1,096,101	971,934
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	152,580

Quarterly Financial Data (Unaudited) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Data [Line Items]
Revenue	$ 38	$ 38	$ 182	$ 376	$ 226	$ 133	$ 110	$ 50	$ 634	$ 519	$ 1,549
Operating loss	(13,313)	(13,528)	(14,639)	(13,540)	(11,090)	(9,441)	(7,889)	(9,721)	(55,020)	(38,142)	(28,897)
Net loss before noncontrolling interest	(13,711)	(13,505)	(14,617)	(13,520)	(11,059)	(9,822)	(10,412)	(9,813)	(55,353)	(41,107)	(36,101)
Net loss	$ (4,050)	$ (3,993)	$ (4,457)	$ (3,852)	$ (3,169)	$ (4,103)	$ (10,412)	$ (9,813)	$ (16,352)	$ (27,498)	$ (36,101)
Class A Common Stock [Member]
Quarterly Financial Data [Line Items]
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.42)	$ (0.41)	$ (0.47)	$ (0.42)	$ (0.35)	$ (0.49)	$ (1.33)	$ (1.26)	$ (1.71)	$ (3.32)

Predecessor Financial Arrangements - Additional Information (Detail) - USD ($) $ in Millions		12 Months Ended
	Aug. 28, 2015	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2014	Dec. 30, 2014	Mar. 28, 2014	Mar. 30, 2007
M&F TTP Holdings LLC [Member] \| Note and Equity Issuance Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Outstanding principal and interest due						$ 116.2
TransTech Pharma, LLC (TTP) [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Principal amount of perpetual securities					$ 6.0
TransTech Pharma, LLC (TTP) [Member] \| Perpetual Securities [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Initial fair value of securities recorded					6.6
Increase in fair value of perpetual securities		$ 0.1
TransTech Pharma, LLC (TTP) [Member] \| M&F TTP Holdings LLC [Member] \| Series F Redeemable Convertible Preferred Units [Member] \| Note and Equity Issuance Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Redeemable convertible preferred units, issued						292,722,844
High Point Pharmaceuticals, LLC (HPP) [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Principal amount of perpetual securities					0.5
High Point Pharmaceuticals, LLC (HPP) [Member] \| M&F TTP Holdings LLC [Member] \| Series B Redeemable Convertible Preferred Units [Member] \| Note and Equity Issuance Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Redeemable convertible preferred units, issued						155,219,376
vTv Therapeutics Holdings \| Class B Common Stock [Member] \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Number of shares or units transferred	1,344,186
vTv Therapeutics Holdings \| vTv Units [Member] \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Number of shares or units transferred	1,344,186
vTvx Holdings One \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Principal amount of notes and securities repurchased	$ 6.0
vTvx Holdings One \| Class A Common Stock [Member] \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Number of shares of Class B common stock exchanged for shares of Class A common stock	1,344,186
vTvx Holdings Two \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Principal amount of notes and securities repurchased	$ 0.5
Former Officer [Member] \| High Point Pharmaceuticals, LLC (HPP) [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Percentage of ownership interest in subsidiary transferred				100.00%
Former Officer [Member] \| 2007 Note [Member] \| TransTech Pharma, LLC (TTP) [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Receivable due from a related party, net							$ 4.8
Former Officer and Related Entities [Member] \| Other Liabilities [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Periodic cash payments to former officer and related entities, Total			$ 7.5
Cash payments to former officer and related entities at closing of the agreement					$ 2.5
Periodic cash payments to former officer and related entities			$ 5.0

Fair Value of Financial Instruments - Summary of Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Purchases/Issuance	$ 167
Balance at December 31	167
Balance at January 1		$ 449,935	$ 14,676
Net Change in fair value included in earnings		115
Net change in fair value		67,074	399,106
Purchases/Issuance	167	0	90,547
Sales/Repurchases	0	0	(54,394)
Effect of Reorganization Transaction		(517,124)
Balance at December 31	167		449,935
Significant Unobservable Inputs (Level 3) [Member] \| Convertible Payable [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1		4,897
Purchases/Issuance		0	4,897
Sales/Repurchases		0
Effect of Reorganization Transaction		(4,897)
Balance at December 31			4,897
Significant Unobservable Inputs (Level 3) [Member] \| Notes Payable [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1		6,594
Net Change in fair value included in earnings		115
Purchases/Issuance		0	6,594
Sales/Repurchases		0
Effect of Reorganization Transaction		(6,709)
Balance at December 31			6,594
Significant Unobservable Inputs (Level 3) [Member] \| TTP Redeemable Preferred Securities [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1		412,085	14,676
Net change in fair value		66,379	399,106
Purchases/Issuance		0	52,697
Sales/Repurchases		0	(54,394)
Effect of Reorganization Transaction		(478,464)
Balance at December 31			412,085
Significant Unobservable Inputs (Level 3) [Member] \| HPP Redeemable Preferred Securities [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Purchases/Issuance		0
Sales/Repurchases		0
Significant Unobservable Inputs (Level 3) [Member] \| Contingent Distribution [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1		26,359
Net change in fair value		695
Purchases/Issuance		0	26,359
Sales/Repurchases		0
Effect of Reorganization Transaction		$ (27,054)
Balance at December 31			$ 26,359
Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Purchases/Issuance	167
Balance at December 31	167
Fair Value, Measurements, Recurring [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	167
Fair Value, Measurements, Recurring [Member] \| Warrant Liability [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	167
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	167
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	$ 167

Fair Value of Financial Instruments - Summary of Significant Inputs Utilized in the Valuation of Warrant Liability (Detail) - Warrant Liability [Member]		12 Months Ended
	Oct. 28, 2016	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Annual volatility	82.54%	83.28%
Annual risk-free rate	1.63%	2.30%